Antion Biosciences SA has been granted a significant patent by the United States Patent and Trademark Office (USPTO), strengthening its position as a leading innovator in cell and gene therapy. The patent grants exclusive worldwide rights to Antion’s gene silencing technologies, which allow for efficient, tunable, and multiplex engineering of cell and gene therapy products. Antion’s CEO, Dr. Marco Alessandrini, expressed pride in the achievement and highlighted the company’s commitment to improving its platform of technologies. The patent also opens opportunities for partnerships and the development of a robust portfolio of universal therapies. Antion Biosciences is a Swiss-based biotechnology company focused on developing universal cell and gene therapy products for diseases with unmet medical needs.
Antion Biosciences Achieves Major Milestone with Granting of US Patent
GENEVA, Sept. 06, 2023 (GLOBE NEWSWIRE) – Antion Biosciences SA (Antion), a leading developer of cell and gene therapy technologies, is excited to announce the recent issuance of a significant patent by the United States Patent and Trademark Office (USPTO). This newly granted patent, US Patent No. US 11,649,455, further solidifies Antion’s position as an innovative pioneer in the field of cell and gene therapy.
Revolutionizing Gene Silencing Technologies for Enhanced Therapies
Building upon its founding intellectual property (IP) with US 9,556,433, this latest patent empowers Antion to safeguard its proprietary gene silencing technologies. These groundbreaking advancements enable efficient, tunable, and multiplex engineering of cell and gene therapy products. This accomplishment not only highlights Antion’s commitment to progress and innovation, but also validates the team’s tireless efforts in optimizing its platform of technologies.
Dr. Marco Alessandrini, the CEO of Antion, expressed his pride and emphasized the magnitude of this achievement, stating, “The attainment of this pivotal patent is a testament to our innovative prowess and unwavering dedication to improving our technological platform. The exclusive worldwide rights granted reinforce our competitive position in the sector, empowering us to pioneer unique approaches and solidifying our uniquely versatile platform. With our tunable and multiplex cell engineering technology, we can diversify and expand our portfolio of universal therapies while forging strategic partnerships with industry leaders in the cell and gene therapy space.”
About Antion Biosciences
Leading the Way in Universal Cell and Gene Therapy
Antion Biosciences SA is a Swiss-based biotechnology company at the forefront of developing universal cell and gene therapy products to address diseases with significant unmet medical needs. Leveraging their proprietary gene silencing and miCAR™ technologies, Antion adopts a modular and tunable approach to multiplex engineering of therapeutic cells. Their vision is to make cell and gene therapies universally accessible by creating off-the-shelf therapies that offer enhanced potency and improved safety for all patients.
For more information, please visit Antion Biosciences.
Cautionary Note on Forward-Looking Statements
Please note: This announcement may contain forward-looking statements based on current expectations and projections about future events. Various factors, including market conditions, industry trends, and operational risks, may cause actual results to differ materially from those expressed or implied by these forward-looking statements.
Contact Antion Biosciences
Email: media@antionbio.com
Address: Antion Biosciences SA, Chemin des Aulx 12, CTN12, 1228 Plan-les-Ouates, Geneva, Switzerland
